Home > Media Centre
Media Centre
Press releases
AM-PHARMA PROVIDES BUSINESS UPDATE AND OUTCOME OF PRE-PLANNED INTERIM FUTILITY ANALYSIS OF PHASE 3 REVIVAL STUDY
Phase 3 REVIVAL study stopped per recommendation of data…
AM-PHARMA ANNOUNCES PUBLICATION OF IN VIVO ACUTE KIDNEY INJURY STUDY DEMONSTRATING ILOFOTASE ALFA’S DUAL PROTECTIVE MECHANISM
Study shows ilofotase alfa protects against ischemia-reperfusion…
AM-Pharma to Participate in Upcoming Jefferies Healthcare Conference
Utrecht, The Netherlands, June 6, 2022 – AM-Pharma B.V., an…
400 PATIENTS HAVE BEEN ENROLLED IN AM-PHARMA’s PIVOTAL PHASE 3 STUDY OF ILOFOTASE ALFA FOR THE TREATMENT OF SEPSIS-ASSOCIATED ACUTE KIDNEY INJURY
Decision from the first pre-specified futility analysis at…
AM-Pharma to Participate in SVB Leerink Biopharma Private Company Connect
Utrecht, The Netherlands, March 22, 2022 – AM-Pharma B.V.,…
Publications
AM-PHARMA TO PRESENT DATA FROM PHASE 3 REVIVAL STUDY AT UPCOMING SCIENTIFIC CONFERENCES
Principal investigator Professor Peter Pickkers to present…
Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury
You can read the whole publication by clicking on this button
View…
Effects of a human recombinant alkaline phosphatase during impaired mitochondrial function in human renal proximal tubule epithelial cells
View publication
Effects of a human recombinant alkaline phosphatase on renal hemodynamics, oxygenation and inflammation in two models of acute kidney injury
View publication
Human recombinant alkaline phosphatase inhibits ex vivo platelet activation in humans
View publication